Company Overview
Nexentis Technologies Inc. develops and operates an AI and data-driven computational biotech platform with a primary focus on mitochondrial biology, precision oncology, and inflammatory metabolic diseases. The company operates within the Basic Materials sector, specifically the Agricultural Inputs industry, which contextualizes its listing environment despite its biotechnology operational focus. Nexentis maintains a market capitalization of $3.32M, reports annual revenue of $209,000, and employs 3 individuals to execute its strategic objectives. These financial figures indicate that the company functions as a micro-cap entity with minimal revenue generation relative to its market valuation, suggesting a business model reliant on potential future asset appreciation or capital deployment rather than current operational profitability. The disparity between the $3.32M market cap and the $209,000 in TTM revenue highlights a valuation structure where the market price is decoupled from traditional earnings-based metrics, a common characteristic for early-stage biotechnology firms where investor sentiment drives price more than current cash flow.
Financial Health
The company reported a trailing twelve-month revenue of $209,000 alongside a net income of $-6,942,000 and an EBITDA of $-6,024,000, revealing a significant structural gap between top-line sales and bottom-line profitability. This substantial discrepancy between the modest revenue figure and the negative net income indicates that the company's cost structure is dominated by high fixed costs or significant research and development expenditures that far exceed its current sales volume. Free cash flow stands at $-3,829,648, which signifies a negative financial flexibility position where the company is burning cash faster than it generates it from operations, necessitating reliance on existing cash reserves or external financing to fund ongoing activities. The gross margin is recorded at 64.6%, suggesting that the cost of goods sold is relatively low compared to revenue, while the operating margin of -66,300.0% and profit margin of 0.0% reflect severe operational inefficiencies or losses that are not yet covered by gross profitability. On the balance sheet, Nexentis holds $6.28M in cash against $1.14M in debt, supported by a debt-to-equity ratio of 13.08 and a current ratio of 4.21. While the debt-to-equity ratio of 13.08 technically indicates a highly leveraged position if equity is small, the robust current ratio of 4.21 and the substantial cash hoard suggest the company possesses adequate short-term liquidity to meet its obligations without immediate distress. The return on equity is -101.6% and the return on assets is -44.8%, metrics that reveal that management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns, a typical scenario for development-stage biotech companies but one that requires successful commercialization to reverse.
Valuation Assessment
The trailing P/E ratio and forward P/E are both listed as N/A due to the absence of positive earnings, implying that traditional earnings-based valuation models cannot be applied to assess the company's expected earnings trajectory at this time. The price-to-book ratio is 0.10, which indicates that the market is valuing the company at a fraction of its book value, suggesting either a deep discount to assets or significant concerns regarding the quality and realizability of those assets. The price-to-sales ratio is 15.90 and the EV/EBITDA is 0.60, where the high multiple relative to sales suggests the market prices in significant future growth expectations despite the low sales figure, while the near-zero EV/EBITDA reflects the inability to value the firm based on current earnings power. The stock has a 52-week high of $29.40 and a 52-week low of $0.64, meaning the current price sits significantly below the high and near the low end of the trading range, reflecting high volatility and speculative pricing. The beta value is 1.81, which means the stock price is expected to be 81% more volatile than the broader market, exposing investors to substantial price swings that amplify both potential gains and losses relative to standard market indices.
Growth & Income
The revenue growth year-over-year is -77.8% and the earnings growth year-over-year is N/A, indicating that the company is contracting in terms of top-line sales and lacks a positive earnings growth trajectory to analyze for relative performance. Since the earnings growth is not calculable due to prior losses, one cannot determine if earnings are growing faster or slower than revenue, but the negative revenue growth implies a contraction in business scale or a shift in market conditions affecting sales. As a non-dividend payer, the company does not distribute a dividend yield or payout ratio to shareholders, which means the company reinvests all available resources, albeit insufficient ones currently, back into its operations and research rather than paying dividends. The overall growth and income profile is characterized by significant revenue contraction, negative returns on capital, and a lack of dividend income, positioning the asset purely as a speculative play on future technological validation rather than a source of current income or stable growth.